

# The Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation

NCT07314047

---

|            |                               |
|------------|-------------------------------|
| Status     | RECRUITING                    |
| Phase      | Not Applicable                |
| Sponsor    | MicroPort NeuroTech Co., Ltd. |
| Enrollment | 116 participants              |

## Key Eligibility Criteria

---

### Inclusion (5)

- Age e 18 and d 80 years at the time of signing the informed consent
- Subjects with brain arteriovenous malformation diagnosed by CT/MRI/DSA
- The target brain arteriovenous malformation is classified by Spetzler-Martin in the range of ` \~ c
- Subjects themselves and/or their guardian are able to understand the purpose of the study, consent to participate, and sign the informed consent form
- Brain arteriovenous malformations deemed suitable for liquid embolic agent intervention as assessed by the investigator

### Exclusion (12)

- Multiple brain arteriovenous malformations
- Brain arteriovenous malformation complicated with blood flow-related aneurysm that may require staged and delayed treatment using other methods within the one-year follow-up period
- Brain arteriovenous malformation with a history of stereotactic radiosurgery within 3 years
- Brain arteriovenous malformation with bleeding within 1 week
- Brain arteriovenous malformation with an expected number of embolizations e 4
- ... and 7 more (see full listing online)

## Locations (1 total)

---

Shanghai Changhai Hospital, Shanghai, Shanghai Municipality, China